Monthly Archives: November 2017

Otsuka Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

November 04, 2017 12:03 PM Eastern Daylight Time TOKYO–(BUSINESS WIRE)–Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced detailed results from the Phase 3 REPRISE trial of tolvaptan, which is under investigation in the United States in patients with autosomal dominant polycystic kidney … Continue reading

Posted in M Loghman-Adham, MD | Leave a comment

U.S. FDA APPROVES AURYXIA® (FERRIC CITRATE) TABLETS AS A TREATMENT FOR PEOPLE WITH IRON DEFICIENCY ANEMIA AND CHRONIC KIDNEY DISEASE, NOT ON DIALYSIS

BOSTON, Nov. 07, 2017 (GLOBE NEWSWIRE) — Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a company focused on bringing innovative medicines to people with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Auryxia for an additional indication. … Continue reading

Posted in M Loghman-Adham, MD | Leave a comment